Pacific Edge takes testing online

MARTA STEEMAN
Last updated 12:44 09/07/2014

Relevant offers

Industries

Chart of the day: How much have Aucklanders' electricity bills risen? Insurers hit with 2500 Cyclone Debbie claims, brace for more Chinese company Binxi withdraws takeover offer for Southland's Blue Sky Meats Queenstown plans for new Holiday Inn Express unveiled Xero finds machine-learning from the cloud will be trickier than expected Australian mining boss Gina Rinehart turns to netballers to cut costs at Roy Hill mine Xero passes million-customer milestone Another New Zealand Post and Kiwibank closes its doors Chart of the day: How many Kiwis are jetting overseas from Auckland Airport? Kiwis for kiwi reap sweet rewards from Whittaker's partnership

Dunedin biotechnology company Pacific Edge will soon offer a urine-testing service for bladder cancer that can be ordered online.

Pacific Edge said today it would be launching the e-commerce platform on its website.

The urine samples would be analysed by the company's Dunedin laboratory.

Pacific Edge has developed a non-invasive technology for diagnosing bladder cancer and called it CXbladder.

Pacific Edge commercial director Brent Pownall said Pacific Edge wanted to provide a readily accessible service to those who had found blood in the urine, haematuria, one of the early indicators of possible bladder cancer.

A detailed test report would be sent to the person's general practitioner or nominated healthcare professional.

"Our goal is to make this technology as readily accessible as buying an icecream from the corner dairy," Pownall said.

The company said the e-commerce site had been approved by Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, and the Therapeutic Advertising Pre-vetting System of the Advertising Standards Authority.

In its statement to the NZX today, Pacific Edge did not reveal the cost of the test.

Pacific Edge's aim is to replace the "uncomfortable" cystoscopy method of detecting bladder cancer used by urologists with its non-invasive test.

It has set up its own testing labs in New Zealand and the United States, while in Australia and Spain it has licensed its technology to existing diagnostic companies.

Its sales of CXbladder have so far been low. The company estimates it could reach $100 million of sales by the end of five years of trading.

It launched the product in the United States a year ago and raised capital late last year to establish a United States sales force.

Government agency, Health Innovation Hub, in February announced it would help to raise awareness of the product.

CXbladder would be considered for use in clinics operated by Auckland, Waitemata, Counties Manukau and Canterbury district health boards, it said.

Ad Feedback

- The Press

Special offers

Featured Promotions

Sponsored Content